Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

Rapid, Automated Test Accurately Detects Tuberculosis in Pediatric Samples

By BiotechDaily International staff writers
Posted on 08 Aug 2013
Image: The Xpert MTB/RIF test cartridge (Photo courtesy of Cepheid).
Image: The Xpert MTB/RIF test cartridge (Photo courtesy of Cepheid).
Image: The GeneXpert System loaded with a test cartridge (Photo courtesy of Cepheid).
Image: The GeneXpert System loaded with a test cartridge (Photo courtesy of Cepheid).
A team of South African investigators compared the effectiveness of a new, automated diagnostic test that simultaneously detects tuberculosis (TB) and rifampicin resistance to classical microscopy and culture methods in pediatric samples.

The World Health Organization (WHO) estimated that in 2011 alone more than 500,000 new cases of TB appeared with nearly 64,000 deaths among those younger than 15 years of age.

The authors of the current study collected nearly 1,500 paired sputum and nasopharyngeal specimens from 354 children who presented at a primary care clinic with symptoms of TB. The samples were analyzed with the Cepheid (Sunnyvale, CA, USA; www.cepheidinternational.com) Xpert MTB/RIF test, and the diagnostic accuracy of the results were compared with the reference standards of culture and smear microscopy.

The Xpert MTB/RIF Test detects both TB and rifampicin resistance high sensitivity even in smear negative, culture positive specimens. The test produces results in two hours and requires no instrumentation other than the GeneXpert System.

Cepheid's GeneXpert System is a closed, self-contained, fully integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.

Results revealed that five children (1%) tested positive for tuberculosis by smear microscopy, 26 (7%) tested positive by Xpert MTB/RIF, and 30 (8%) tested positive by culture. Among children who did not in fact have the disease, the results of the Xpert test reported negative for TB with 99% accuracy. These findings suggest that Xpert MTB/RIF on respiratory secretions is a useful test for rapid diagnosis of pediatric pulmonary tuberculosis in primary care.

Dr. Fred Tenover, senior director of scientific affairs at Cepheid, said, "If you were to inoculate an Xpert MTB/RIF test at the same time you started preparing your acid fast smears, by the time you finished reading the smears, the Xpert MTB/RIF test result would be ready, telling you if your positive acid fast smear was TB and if the strain was resistant to rifampicin, which is an excellent surrogate marker for MDR (multiple drug resistant)-TB. I am sure Koch and Pasteur would not only be delighted with the technological advance, they would probably say, 'It is about time.'"

“There has been a perception amongst health care workers that rapid diagnosis of TB in children would not be possible in primary care, but this study disproves that view, said first author Dr. Heather Zar, professor of pediatrics at the University of Cape Town (South Africa; www.scah.uct.ac.za). “Given our results, widespread adoption of rapid testing for TB and drug resistance in children may substantially improve public health without greatly increasing costs.”

Results of the South African study were published in the August 2013 issue of the journal the Lancet Global Health.

Related Links:

Cepheid

University of Cape Town



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more

Business

view channel

Global Computational Biology Sector Expected to Reach over USD 4 Billion by 2020

The global market for computational biology is expected to reach USD 4.285 billion by 2020 growing at a compound annual growth rate (CAGR) of 21.1%, according to new market research. Steady surge in the usage and application of computational biology for bioinformatics R&D programs designed for sequencing genomes... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.